FINWIRES · TerminalLIVE
FINWIRES

Chewy Seen Heading Into Q1 With Cautious Setup, Oppenheimer Says

By

Chewy (CHWY) is heading into fiscal Q1 results with limited EBITDA upside potential amidst softer pet category trends and a more cautious consumer commentary, Oppenheimer said in a Wednesday note.

The firm said it now looks for Q1 adjusted EBITDA of $238 million, below the Street's $241 million estimate, on revenue growth of 7%, versus consensus at 7.6%.

Oppenheimer said it trimmed its forecasts for the core business, excluding the Modern Animal acquisition, to reflect a more cautious stance.

"On the positive side, valuation metrics are now below prior trough levels. On the negative side, we still see an earnings reset, and investors have punished even beats and raises in our coverage lately," the note said.

Chewy will report its Q1 earnings before markets open on June 10.

Oppenheimer maintained its perform rating on Chewy.

Price: $21.41, Change: $-0.06, Percent Change: -0.30%

Related Articles

Wire

Cognizant Technology Solutions Expands Collaboration With Snowflake

Cognizant Technology Solutions (CTSH) and Snowflake (SNOW) said Wednesday they have expanded their collaboration to accelerate enterprise artificial intelligence adoption via the Snowflake CoCo platform.The collaboration is underpinned by solid adoption of the CoCo platform within Cognizant's AI and analytics practice, according to a statement.As a preferred launch partner for CoCo, Cognizant is launching AI agents to support data engineering, analytics, and business workflows, according to the companies.Price: $53.14, Change: $-2.00, Percent Change: -3.63%

$CTSH$SNOW
Wire

FedEx Entering New Phase After Freight Spin-Off, Q4 EPS Seen Below Consensus, Morgan Stanley Says

FedEx (FDX) is poised to report fiscal Q4 earnings before interest and taxes, and earnings per share modestly below consensus as margin pressures continue to outweigh stable revenue trends, Morgan Stanley said in a Wednesday note.The investment firm said the company is entering a new phase following the spin-off of FedEx Freight (FDXF) and investors are likely to focus on long-term fundamentals.The brokerage added that as both businesses begin operating independently, investors will increasingly focus on the sustainability of normalized margin profiles as the gap between revenue performance and earnings conversion remains a key concern.Morgan Stanley said it expects quarterly EBIT of $1.92 billion, compared with a consensus estimate of $1.99 billion. It expect EPS of $5.58 versus a consensus of $5.92. The brokerage added that consolidated results may be less meaningful following the company's spin-off.For the fiscal Q4, FedEx Express' continued pricing strength, fuel surcharge upside and share gains are likely to be offset by persistent cost headwinds and international trade disruptions. Weaker-than-expected pricing and continued volume pressure at FedEx Freight are expected to weigh on earnings, according to the note.FedEx is scheduled to report its fiscal Q4 results on June 23.Morgan Stanley lowered its price target to $160 from $230, with an underweight rating.Price: $328.37, Change: $-0.63, Percent Change: -0.19%

$FDX$FDXF
Wire

Philip Morris International's US Launch of Zyn Ultra Seen as Potential Catalyst, Morgan Stanley Says

Philip Morris International's (PM) launch of Zyn Ultra nicotine pouches in the US will be a potential catalyst for the stock, Morgan Stanley said in a note emailed Wednesday.In an investor conference Tuesday, the company said it is launching Zyn Ultra in the US this month in 9- and 11-milligram strengths across a range of flavors similar to the original Zyn offerings, which was largely expected after the Food and Drug Administration's new enforcement guidance for nicotine pouches and e-vapor products, according to the note.Philip Morris also stated that its heat-not-burn category in Japan has been roughly matching its expectations, with IQOS holding its market share even after a significant excise tax-driven price increase on April 1, the firm noted.Morgan Stanley said it projected above-consensus growth for the stock in the medium term driven by the continued momentum of IQOS globally, the Zyn Ultra launch pushing US growth, and the planned roll-out of IQOS ILUMA in the US.Morgan Stanley maintained the company's stock rating at overweight and raised the price target to $200 from $190.Price: $176.41, Change: $+2.75, Percent Change: +1.58%

$PM